Login / Signup

Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.

Erik J van HeldenOtto S HoekstraRonald BoellaardChantal RothEmma R MulderHenk M W VerheulCatharina Willemien Menke-van der Houven van Oordt
Published in: PloS one (2016)
ClinicalTrials.gov NCT01691391.
Keyphrases
  • metastatic colorectal cancer
  • small cell lung cancer
  • epidermal growth factor receptor
  • tyrosine kinase